Market news

BOSTON, September 24, 2026--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026

Detailed price information for Verastem Inc (VSTM-Q) from The Globe and Mail including charting and trades.

Verastem's (VSTM) shares are not fully valuing its growth potential, considering a "major upcoming c

Verastem (VSTM) has an average rating of buy and mean price target of $14.67, according to analysts

VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.

BOSTON, September 02, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate at the Wells Fargo 21st Annual Healthcare Conference on Sept. 8 in Boston and present at the following investor conferences:

Verastem (VSTM) outlook: AVMAPKI FAKZYNJA sales momentum funds KRAS G12D pipeline; watch Oct 2026 VS-7375 catalyst, valuation & risks—read now.

The average assessed fair value for Verastem has been cut from $16.13 to $14.75, pointing to a moderate reset in price targets. Analysts link this change to a more cautious stance on competition and revenue assumptions, even as many still focus on how Verastem executes on its pipeline and upcoming catalysts. As you read on, you will see how these shifting targets fit into the broader analyst narrative and what to watch as it evolves. Analyst Price Targets don't always capture the full story...

Motley Fool Press Release.

Verastem (VSTM) has an average rating of buy and mean price target of $14.75, according to analysts

Verastem (NASDAQ:VSTM) reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance. The company also reported $15 million

BOSTON, August 06, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress.

BOSTON, July 28, 2026--Verastem doses first patient in TARGET-D 203, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated metastatic colorectal cancer

BOSTON, July 23, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET.

BOSTON, July 22, 2026--Verastem doses first patient in TARGET-D 202, a registration-directed Phase 2 clinical trial of VS-7375 in KRAS G12D-mutated advanced NSCLC.

Verastem Inc. (NASDAQ:VSTM) is one of the 10 best stocks under $10 that could triple. On July 7, RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ:VSTM). The firm reduced the target price from $15 to $14, which still offers a revised upside potential of over 211%. The price target adjustment accompanies the firm’s […]

Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Verastem, Inc. (NASDAQ:VSTM) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 24, RBC Capital reiterated an Outperform rating on Verastem, Inc. (NASDAQ:VSTM) with a $15 price target. The firm noted that the bullish sentiment is based on the company’s G12D inhibitor drug program. ​The firm noted that the […]